FDA approves Retatrutide this year?
12%
Real price history (past month), from Polymarket. Down-sampled to 24 points.
Context
Retatrutide, Eli Lilly's experimental triple-action obesity and metabolic disease treatment, faces low odds of gaining FDA approval before year-end despite advancing clinical trials.
| Implied probability (Yes) | 12% |
|---|---|
| 24h change | +0 pt |
| 7d change | +0 pt |
| Market volume | $576K |
| Resolves by | 2026-12-31 |
| Source | Polymarket ↗ · as of 2026-07-07 |
This is an implied probability from a real-money prediction market (Polymarket), shown as information — not a forecast we endorse and not financial or trading advice. Markets can be thin or move fast; always check the source. Odds ≠ advice.